Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.41 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.41 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 3/20 | 0.40 |
| ▸ | AGXT | P21549 | 1/20 | 0.40 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6025944 | 0.83 | TSHR (0.48) | TSHRIDO1SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL3292550 | 0.82 | TSHR (0.43) | TSHRIDO1SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL7302683 | 0.78 | TSHR (0.48) | TSHRRCE1IDO1SLC1A3SLC1A2 | |
| SCHEMBL19223076 | 0.78 | TSHR (0.48) | TSHRRCE1IDO1SLC1A3SLC1A2 | |
| SCHEMBL7302690 | 0.78 | TSHR (0.48) | TSHRRCE1IDO1SLC1A3SLC1A2 | |
| SCHEMBL5503634 | 0.78 | TSHR (0.48) | TSHRRCE1IDO1SLC1A3SLC1A2 | |
| SCHEMBL10344292 | 0.78 | TSHR (0.52) | TSHRIDO1SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL683166 | 0.77 | RCE1 (0.47) | TSHRRCE1IDO1SLC1A3SLC1A2 | |
| SCHEMBL10528179 | 0.76 | RCE1 (0.48) | TSHRRCE1IDO1SLC1A3SLC1A2 | |
| SCHEMBL1456871 | 0.75 | TSHR (0.44) | TSHRRCE1IDO1SLC1A3SLC1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4653419-A1 | LINKER FOR ANTIBODY-DRUG CONJUGATES, AND ANTIBODY-DRUG CONJUGATE | Otsuka Pharmaceutical Co., Ltd. (JP) | 2025-11-26 | — | — | EP | disclosed |
| WO-2024154763-A1 | LINKER FOR ANTIBODY-DRUG CONJUGATES, AND ANTIBODY-DRUG CONJUGATE | 大塚製薬株式会社 | 2024-07-25 | — | — | WO | disclosed |
| WO-2017031209-A1 | TUBULYSIN ANALOGS AND METHODS | ENDOCYTE, INC. (US) | 2017-02-23 | — | — | WO | disclosed |
| EP-1961750-B1 | VLA-4 INHIBITORY DRUG | DAIICHI SANKYO CO LTD (JP) | 2013-09-18 | — | — | EP | disclosed |
| US-20130065882-A1 | VLA-4 inhibitory drug | MACHINAGA NOBUO (JP) | 2013-03-14 | — | — | US | disclosed |
| US-20120157437-A1 | VLA-4 INHIBITORY DRUG | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-06-21 | — | — | US | disclosed |
| US-8129366-B2 | VLA-4 inhibitory drug | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-03-06 | — | — | US | disclosed |
| US-20090233901-A1 | VLA-4 INHIBITORY DRUG | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-09-17 | — | — | US | disclosed |
| EP-1961750-A1 | VLA-4 INHIBITORY DRUG | Daiichi Sankyo Company, Limited (JP) | 2008-08-27 | — | — | EP | disclosed |
| EP-1414384-A4 | SYNTHESIS OF EPOTHILONES AND RELATES ANALOGS | UNIV MISSISSIPPI (US) | 2005-07-27 | — | — | EP | disclosed |
| EP-1414384-A2 | SYNTHESIS OF EPOTHILONES AND RELATES ANALOGS | The University of Mississippi (US) | 2004-05-06 | — | — | EP | disclosed |
| WO-2002081441-A1 | PROCESS FOR THE PREPARATION OF SUBSTITUTED PYRROLIDINE NEURAMINIDASE INHIBITORS | ABBOTT LABORATORIES (US) | 2002-10-17 | — | — | WO | disclosed |
| WO-2002030356-A2 | SYNTHESIS OF EPOTHILONES AND RELATES ANALOGS | THE UNIVERSITY OF MISSISSIPI (US) | 2002-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157437-A1 | VLA-4 INHIBITORY DRUG | VCAM1, ITGB4, ITGA4 | TSHR 2972/4885RCE1 991/4885IDO1 3042/4885 |
| US-20130065882-A1 | VLA-4 inhibitory drug | VCAM1, ITGB4, ITGA4 | TSHR 3047/4885RCE1 951/4885IDO1 3142/4885 |
| US-20090233901-A1 | VLA-4 INHIBITORY DRUG | VCAM1, ITGB4, ITGA4 | TSHR 3028/4885RCE1 1086/4885IDO1 3688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.